A guadecitabine-specific gene signature, that we recently identified in-vitro in melanoma cell lines treated with this DNMT inhibitor [29], was selectively activated in on-treatment tumor biopsies of responding patients compared to non-responding ones in the NIBIT-M4 trial [63]. This evidence concerns the gene DNMT1 and neoplasm.